Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Gilead Sciences
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: August 9, 2013
Last updated: August 31, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2033
  Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)